Clinical trial

Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not…

NCT00121667 · AstraZeneca, Industry · Completed

Key facts

NCT number NCT00121667
Title Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
Official title "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone"
Lead sponsor AstraZeneca, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Diabetes Mellitus, Type 2
Intervention type Drug
Interventions Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
Enrollment 1,462
Start date Aug 1, 2005
Primary completion Oct 1, 2006
Completion Feb 1, 2010
First posted Jul 21, 2005
Last update posted Apr 29, 2015
Countries Argentina, Australia, Brazil, Canada, Chile, Mexico, Puerto Rico, Taiwan, United States

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies